Responding to Disruptions in Scientific Funding

·1 hr 1 min·4 clips

Fierce reported over $1.8 billion in NIH cuts and 684 grant programs wiped out.

1. cc: Life Science Podcast centers on responding to disruptions in scientific funding and the marketing choices that follow them. 2. Host Hamid Ghandan brings reports from Persuading Scientists and Catalytic Experiences, while guest Elizabeth Schaub brings High Touch Group and The Giant's Ladder. 3. The episode asks how life-science companies should market and plan when NIH cuts, tariffs, and budget freezes change the business landscape. 4. Elizabeth Schaub cites Fierce reporting on more than $1.8 billion in NIH cuts and 684 grant programs being wiped out. 5. She says those cuts damage the innovation pipeline from basic research into preclinical and translational work. 6. She points to France, Germany, Singapore, China, Saudi Arabia, and the UAE as countries trying to attract U.S. researchers. 7. Hamid Ghandan describes conversations with VC and private equity people who see long-term fundamentals as strong while the immediate term is frozen. 8. He says that freeze reaches marketing, sales, and every business function because nobody knows what to bet on. 9. Elizabeth Schaub summarizes three studies from the year: a semi-annual state of science report, an NIH indirect-funding report, and a tariffs report. 10. She says academia was forecasting a 10% budget cut, while biopharma budgets were up 2%, which still meant a reduction after inflation. 11. Schaub reports that consumer sentiment in life sciences was 68%, meaning respondents still expected to meet yearly goals. 12. She says the February NIH report found that the vast majority expected to be negatively affected, while a small minority saw an opportunity to reset. 13. She says the tariffs report found four concerns in academia: access to technology, shrinking budgets and capabilities, long lead times, and supply security. 14. Schaub says 63% of respondents worried about supply security and reliability after the COVID-era supply chain disruptions. 15. Ghandan says 18% of February respondents were considering another job, which could mean leaving academia, moving to industry, or changing geography. 16. He argues that companies still have a multi-hundred-billion-dollar life-sciences market, but the money is concentrating into fewer, better-funded bets. 17. Schaub says that in this environment, companies are rethinking the commercial function of the future through pilot programs and budget thought exercises. 18. Ghandan and Schaub frame the tone as practical, candid, and focused on strategy rather than speculation. 19. Listeners in life-science marketing, commercial leadership, and research strategy will get the most value. 20. Listeners wanting a science-news recap without business strategy may skip it.

As heard by us

A clear life-science marketing and budget discussion that favors longer-term judgment under uncertainty.

This discussion looks at how life-science companies should make marketing and budget choices while tariffs and uncertainty keep shifting the ground.

Read the full review in PlayNext →

Why you'd press play

When budgets get shaky, this helps you think about marketing with a longer view.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from cc: Life Science Podcast